Enhanced lysis by bispecific oncolytic measles viruses simultaneously using HER2 /neu or EpCAM as target receptors
Jan R.H. Hanauer(Paul Ehrlich Institut), Michael D. Mühlebach(Paul Ehrlich Institut), Klaus Cichutek(Paul Ehrlich Institut), Dennis Riehl(Johannes Gutenberg University Mainz), Thorsten Friedel(Paul Ehrlich Institut), Christian J. Buchholz(Goethe University Frankfurt), Steffen Prüfer(Paul Ehrlich Institut), Christian Jöst(ZHAW Zurich University of Applied Sciences), Katrin Friedrich(Paul Ehrlich Institut), Tillmann Rusch(Goethe University Frankfurt), Vivian Koch(Paul Ehrlich Institut), Lisa Gottschlich(Paul Ehrlich Institut), Andreas Plückthun(University of Zurich), Robert C. Münch(Paul Ehrlich Institut), Kay-Martin Hanschmann(Paul Ehrlich Institut), Stefan Hutzler(Paul Ehrlich Institut)
Cited by 22
Related Papers
Patient Blood Management
|JAMA|2019|619
In vivo generation of human CD19‐CAR T cells results in B‐cell depletion and signs of cytokine release syndrome
|EMBO Molecular Medicine|2018|188
A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform
|Journal of Virology|2015|124
Bispecific Designed Ankyrin Repeat Proteins (DARPins) Targeting Epidermal Growth Factor Receptor Inhibit A431 Cell Proliferation and Receptor Recycling
|Journal of Biological Chemistry|2011|109